Enter your ZIP code:

Please enter a 5 digit zipcode
No results...

Entering your zip code helps us to provide information and results that are more relevant to you.

Your privacy is important to us. By continuing, you agree to our Privacy Policy.





Phase I/Ib Single Arm, Open-label Trial of Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects with GPC3+ Unresectable Hepatocellular Carcinoma (HCC)

Cancer
Shyam Srinivas
Liver

Study Description

A single arm, open-label Phase 1/1b study of the theranostic pair RYZ811 (diagnostic) and RYZ801 (therapeutic) to identify and treat subjects with GPC3+ unresectable HCC

Eligibility

  • Age of at least 18 years at the time of signing the informed consent form

-Histologically/cytologically confirmed diagnosis of Hepatocellular Carcinoma (HCC)

-Dose Escalation Only: Disease progression after receipt of at least 1 prior systemic therapy for unresectable HCC

Dose expansion only: Disease progression after receipt of one prior systemic therapy for unresectable HCC

  • Patients with fibrolamellar carcinoma, sarcomatoid HCC or combined hepatocellular cholangiocarcinoma

-Prior liver transplantation

  • Pregnancy or breastfeeding
A female nurse attentively holds a tablet, ready to assist with patient care and medical information.

Interested in Participating in this Trial?

Thank you for your interest with our team.

One of our specialists will be in contact with you soon.